Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Eight For 8: Things You Need To Know About China Biopharma Commercial In 2018

Dec 27 2018

• By Brian Yang

Happy New Year 2018 — 2018 China Biopharma Commercial Roundup • Source: Shutterstock

Related Content

Art Of War: Why Pharma Must Do Digital Dance In China

Sep 04 2018

Winner Takes All: New China Bidding Scheme Marks Price Watershed?

Nov 20 2018

China Vs. Cancer: Coverage For 17 Drugs Unveils Price Pressures, Commercial Battleground

Oct 12 2018

China Biotech Innovation Reaching Tipping Point?

Oct 15 2018

Downward, Eastward or Inward? Blockbuster Film Puts Cancer Drug Prices In China Spotlight

Jul 11 2018

AI-Powered 'Doctor' Adds Fuel To China Digital Health Investment Fire

Nov 13 2018

Mixed Views On Hong Kong Market's Role Despite IPOs Lining Up

Sep 11 2018

Set, Ready, Afford: China Rushes To Access Innovation Amid New Drug Dash

Dec 05 2018

Drug Price Waterloo: China's New Bidding Process Hits MNCs Hard

Dec 11 2018

China Zero Tariffs For Cancer Drugs Precede High-Stakes Trade Talks

May 07 2018

Related Companies

Eli Lilly and Company

Roche Holding AG

Luye Pharma Group, Ltd.

BeOne Medicines Ltd.

AstraZeneca PLC

Sanofi

Merck & Co., Inc.

Johnson & Johnson

Ascletis Pharma, Inc.

Innovent Biologics, Inc.

Bristol Myers Squibb Company

Additional Topics

China Asia Pacific Commercial Digital Health Pricing Strategies BioPharmaceutical

More from China

More from Focus On Asia

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window